Physician profile
Latonya Mann
NPI 1649675620
$3,247.31
in general payments reported to CMS, 2019-2025
20 companies · $565 in 2025
The $565 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.25 · 2022: $375 · 2023: $551 · 2024: $1,740 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,787 · Education: $69.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,787.06 |
| Education | $69.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,215.66 | 2023-2025 | Fasenra, Airsupra, Imfinzi |
| Pfizer INC. | $145.96 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $135.32 | 2025 | |
| Xeris Pharmaceuticals, INC. | $135.00 | 2025 | Gvoke Hypopen |
| Novo Nordisk INC | $125.56 | 2024-2025 | Ozempic, Wegovy |
| Daiichi Sankyo INC. | $125.00 | 2024 | |
| Seagen INC. | $125.00 | 2022 | |
| Gilead Sciences, INC. | $125.00 | 2023 | Epclusa |
| Sobi, INC | $125.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 | Jardiance |
| Eisai INC. | $125.00 | 2024 | |
| Karyopharm Therapeutics INC. | $125.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $110.04 | 2024 | Xarelto |
| Btg International INC. | $109.74 | 2024 | |
| Lilly USA, LLC | $100.00 | 2024 | Mounjaro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $98.84 | 2023 | Pomalyst |
| Beigene USA, INC. | $77.88 | 2023 | Brukinsa |
| Glaxosmithkline, LLC. | $68.97 | 2025 | Nucala, Fluarix Quadrivalent |
| Janssen Biotech, INC. | $33.09 | 2025 | Rybrevant, Carvykti |
| Abbvie INC. | $16.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latonya Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.